Inquiry Basket
CAS No.: 159858-33-0
Cat No.: BADC-00969
Purity: >98.0%
4.5 
Val-Cit is a widely used cleavable dipeptide ADC linker enabling protease-sensitive payload release. Essential for antibody-drug conjugate development targeting tumor-specific environments with high therapeutic precision.
Structure of 159858-33-0
* For research and manufacturing use only. We do not sell to patients.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
Val-Cit is a widely used cleavable linker in antibody-drug conjugate (ADC) design, featuring a valine-citrulline dipeptide sequence that enables selective intracellular payload release. In ADC linker design, Val-Cit acts as a protease-sensitive cleavable unit, allowing controlled release of ADC cytotoxins specifically within lysosomal compartments of tumor cells. Its chemical structure ensures high stability in circulation while maintaining efficient cleavage upon internalization. Val-Cit’s incorporation into ADCs enhances modular linker design, allowing the attachment of diverse payloads while preserving antibody functionality and pharmacokinetic performance.
In payload conjugation applications, Val-Cit is compatible with a broad spectrum of ADC cytotoxins, including microtubule inhibitors, DNA-intercalating agents, and other potent therapeutic molecules. The dipeptide sequence is selectively cleaved by cathepsin B and other lysosomal proteases, providing tumor-specific payload release. Val-Cit can be combined with various linker architectures, such as PEG spacers or self-immolative PABA groups, to optimize solubility, flexibility, and stability. Researchers leverage Val-Cit to construct homogeneous ADCs with predictable release profiles, enhancing both efficacy and safety in preclinical and clinical development.
From an application perspective, Val-Cit is extensively applied in oncology-focused ADC research, targeted drug delivery studies, and protease-sensitive bioconjugation strategies. Its unique dipeptide structure enables highly selective payload release while maintaining linker stability in circulation. By integrating Val-Cit into ADC linker design, developers can create tunable, cleavable linker-payload conjugates that maximize therapeutic potential, providing precise intracellular delivery tailored to the tumor microenvironment without compromising antibody integrity.
| Catalog | Product Name | CAS | Inquiry |
|---|---|---|---|
| BADC-01058 | Acid-propionylamino-Val-Cit-OH | 2098907-84-5 | |
| BADC-01279 | MC(C5)-Val-Cit | 2504147-59-3 | |
| BADC-01178 | Boc-Val-Cit-OH | 870487-08-4 | |
| BADC-01255 | DBCO-Val-Cit-OH |
What is the primary application of Val-Cit in ADCs?
Val-Cit is a dipeptide linker commonly used in antibody-drug conjugates, designed to be cleaved by cathepsin B and related proteases in lysosomal compartments, ensuring selective payload release.
1/5/2022
Dear team, how does Val-Cit ensure selective release of cytotoxins?
The Val-Cit linker remains stable in circulation but is efficiently cleaved by lysosomal proteases within target cells, providing a high degree of specificity and minimizing systemic toxicity.
29/8/2020
Could you kindly advise which types of ADC payloads are compatible with Val-Cit?
Val-Cit is compatible with a variety of cytotoxic agents, including MMAE and other auristatin derivatives, through carbamate or amide linkage strategies without altering antibody function.
16/3/2022
Dear Sir, what factors should be considered when optimizing Val-Cit linkers?
Optimization factors include peptide sequence confirmation, linker length, steric hindrance effects, and evaluation of intracellular cleavage rates to maximize therapeutic efficacy.
8/6/2019
Good afternoon! Which detection and verification methods would you suggest for Val-Cit?
Val-Cit identity and structural integrity can be confirmed using NMR, HPLC, and mass spectrometry. Proper storage at -20°C under dry conditions is recommended to maintain dipeptide stability. Aliquoting reduces the risk of degradation, ensuring reliable performance in antibody-drug conjugate applications.
12/5/2018
— Dr. Natalie Brown, Bioconjugation Scientist (USA)
Val-Cit linker demonstrated excellent enzymatic cleavage, ensuring precise payload release in ADCs.
16/3/2022
— Prof. Henrik Larsen, Medicinal Chemist (Denmark)
High batch-to-batch reproducibility of Val-Cit made scaling our ADC program seamless.
12/5/2018
— Dr. Sofia Moretti, Protein Chemist (Italy)
BOC Sciences’ Val-Cit linker showed consistent quality and high purity, facilitating conjugation.
8/6/2019
— Ms. Emily Thompson, R&D Manager (UK)
Using Val-Cit linker, we achieved reproducible conjugation yields with minimal side reactions.
1/5/2022
— Dr. Marcus Schmidt, Bioconjugation Specialist (Germany)
Excellent solubility and stability profile of Val-Cit improved our workflow efficiency.
— Mr. Daniel Johnson, Research Scientist (Canada)
Val-Cit linker facilitated high-throughput ADC screening with reliable payload release.
29/8/2020
Val-Cit
Required fields are marked with *
Val-Cit
Required fields are marked with *
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.
